Home › Companies › KOD

Kodiak Sciences Inc.

KOD Lead: Phase 3 3 Biotech Distilled articles ↓

Ophthalmology Protein

Most recent annual filing: 2026-03-31

Pipeline (7 active programs)

Zenkuda

tarcocimab tedromer · tarcocimab · KSI-301

Protein Target: VEGF

Wet Age-Related Macular Degeneration Phase 3 intravitreal
Diabetic Retinopathy Phase 3 intravitreal
Retinal Vein Occlusion Phase 3 intravitreal

Undisclosed indication Preclinical

KSI-103

Protein Target: IL-1, IL-6

Undisclosed indication Preclinical

Technology platforms

ABC Platform

Antibody Biopolymer Conjugate platform merging protein-based and chemistry-based therapies via molecular engineering; focus on retinal vascular diseases and ocular inflammation; enables high drug-antibody-ratio medicines via ABCD extension embedding small molecules into biopolymer backbone

Targets: VEGF, IL-6

ABCD Platform

Antibody Biopolymer Conjugate Drug platform extending ABC to embed small molecule APIs into the biopolymer backbone for high drug-antibody ratio medicines; advancing duet programs for glaucoma (NLRP3 inhibitor + IOP-lowering molecule) and geographic atrophy (complement inhibitor + NLRP3 inhibitor); focus on ophthalmic and systemic multifactorial diseases.

Targets: NLRP3

VETi

Visual Engagement Technology and Imager — AI- and machine-learning-enabled wearable headset platform with applications in retina care, identity security, and cognitive sciences

Biotech Distilled coverage (3)

2026-05-08 UPDATE: Kodiak Sciences (KOD) - The Going Concern Footnote Nobody is Reading 🔒 Paid
2026-03-29 UPDATE: Kodiak Sciences (KOD) - The Franken-Formulation Gets Vindicated (and a New Name) 🔒 Paid
2026-01-29 Kodiak Sciences (KOD): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.